Ocriplasmin
Ocriplasmin
Ocriplasmin (microplasmin) is a truncated form of the human serine protease plasmin that retains its enzymatic properties.
Ocriplasmin (microplasmin) is a small molecule designed specifically for use in the eye and is being studied for the treatment of symptomatic vitreomacular adhesion. Ocriplasmin (microplasmin) is believed to primarily target the fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina.
Ocriplasmin (microplasmin) is delivered via an intravitreal injection.
The goal of any pharmacologic separation of the vitreoretinal interface is to create a clean separation of the posterior vitreous cortex and the inner limiting membrane (ILM) of the retina. Compared to mechanical separation by vitrectomy surgery, pharmacologic options may provide a bare ILM with no residual vitreous, adhesions, or collagen remnants.1,2The vitreous then separates fully from the
retina, and the sVMA is resolved.
retina, and the sVMA is resolved.
1. Gandorfer A, Putz E, Welge-Lüssen U, Grüterich M, Ulbig M, Kampik A. Br J Ophthalmol. 2001;85(1):6-10.
2. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Invest Ophthalmol Vis Sci. 2005;46(9):3295-3299.